We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App

New Diagnostic Approach Combines DNA Testing With AI Analysis for Coronary Heart Disease Risk Assessment

By LabMedica International staff writers
Posted on 31 May 2023
Print article
Image: PrecisionCHD offers 75% higher sensitivity than conventional testing methods (Photo courtesy of Cardio Diagnostics)
Image: PrecisionCHD offers 75% higher sensitivity than conventional testing methods (Photo courtesy of Cardio Diagnostics)

Despite significant progress in medical science, heart disease continues to be a leading cause of death across the globe. Early diagnosis is key for implementing preventive actions, but current methods often entail high costs, exposure to harmful radiation and contrast agents, and extensive wait times, sometimes 4-6 weeks, for scheduling and receiving results from tests such as the echo stress exam. Now, a revolutionary test utilizes epigenetics, genetics, artificial intelligence, and machine learning to more accurately and cost-effectively detect early signs of cardiovascular disease.

Cardio Diagnostics Inc.’s (Chicago IL, USA) new test, PrecisionCHD, employs cutting-edge technology to offer sensitivity that's 75% higher than conventional methods, while also delivering results up to two-thirds faster. This ground-breaking development promises to transform heart disease detection and treatment for the health-conscious generation. PrecisionCHD only requires a single blood sample, which can be collected at a doctor's office or at home using a lancet. This novel test harnesses the power of epigenetics and genetics in conjunction with artificial intelligence, offering unprecedented accuracy and speed in detecting coronary heart disease. Furthermore, the six epigenetic indices that are the foundation of PrecisionCHD enable physicians to use Cardio Diagnostics' Actionable Clinical Information platform to tailor treatment to the patient's unique risk profile. PrecisionCHD eliminates guesswork concerning the causes of heart disease, providing a clear, comprehensible picture of the underlying biology.

PrecisionCHD outperforms traditional methods in terms of cost-effectiveness and accuracy, with 75% higher sensitivity. This means it can identify diseases at earlier stages and lower thresholds than ever before. This innovative approach also circumvents the need for expensive echo stress tests, as it can provide reliable results up to two-thirds faster, making it ideal for individuals requiring prompt, accurate diagnosis. In addition to being faster and more accurate, PrecisionCHD offers scalable heart health solutions that can be deployed globally. Its accuracy isn't compromised by geographical location or access to healthcare, making it a viable response to the growing demand for cardiovascular solutions in today's world. This scalability ensures its suitability for both developing nations with limited resources and developed countries where healthcare access can be costly and time-consuming.

“The launch of PrecisionCHD represents a leap forward in cardiovascular medicine. I’m beyond thrilled that we’re able to make the promise of precision cardiovascular medicine a reality,” said Robert Philibert, MD Ph.D., the company’s Chief Medical Officer and Co-Founder. “Clinicians seeking to assess coronary heart disease status in their patients no longer have to worry about their ability to obtain an exercise stress test or angiogram. Now, clinicians can have a blood sample drawn in their office or a kit sent to their patient’s home for this highly sensitive test.”

Related Links:
Cardio Diagnostics Inc. 

Platinum Supplier
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Gold Supplier
Digital Pathology Solution
Agglutination Plates
Near-Patient Testing Platform

Print article


Clinical Chemistry

view channel
Image: The new assays are designed to run on the B•R•A•H•M•S KRYPTOR compact PLUS clinical chemistry analyzer (Photo courtesy of Thermo Fisher)

Breakthrough Immunoassays to Aid in Risk Assessment of Preeclampsia

Preeclampsia is a life-threatening blood pressure condition that can arise during pregnancy and the postpartum phase. This severe pregnancy complication is a primary cause of maternal and fetal mortality... Read more


view channel
Image: The US FDA has cleared HemoScreen point of care CBC for direct capillary sampling (Photo courtesy of PixCell Medical)

Point of Care CBC Analyzer with Direct Capillary Sampling Enhances Ease-of-Use and Testing Throughput

The world’s only 5-part differential Complete Blood Count (CBC) analyzer that is FDA-cleared, CE-marked, and TGA-approved for point-of-care use has now been granted FDA 510(k) clearance for direct capillary... Read more


view channel
Image: Immune cells present long before infection predict flu symptoms (Photo courtesy of Shutterstock.com)

Single Blood Draw to Detect Immune Cells Present Months before Flu Infection Can Predict Symptoms

For decades, if not centuries, scientists have struggled to solve the mystery of why certain individuals fall ill to infections while others remain unaffected. In an impressive development, researchers... Read more


view channel
Image: The rapid diagnostic test could pinpoint the correct antibiotic for infection treatment in under an hour (Photo courtesy of Microplate Dx)

Point-of-Care Device to Reduce Antibiotic Susceptibility Testing Time from Days to Minutes

Antimicrobial resistance (AMR) is a significant global health issue, currently leading to over 1.27 million deaths worldwide each year. By 2050, AMR could be causing up to 10 million deaths annually, surpassing... Read more


view channel
Image: The Tasso+ device has received CE Mark certification (Photo courtesy of Tasso)

Groundbreaking Blood Lancing Device Obtains Microliter Capillary Whole Blood Samples Painlessly

A convenient, virtually pain-free blood lancet that collects whole liquid blood samples has received CE Mark designation, making the patient-centric, high-volume blood collection solution available in... Read more


view channel
Image: A new electrochemical device can quickly and inexpensively identify people at greatest risk for osteoporosis (Photo courtesy of ACS Central Science, 2023)

Electrochemical Device Identifies People at Higher Risk for Osteoporosis Using Single Blood Drop

With the global increase in life expectancy, the incidence of age-related conditions like osteoporosis is increasing. Osteoporosis, affecting around 200 million individuals worldwide, has a higher incidence... Read more


view channel
Image: The global fully automatic electrolyte analyzers market is projected to reach close to USD 0.77 billion by 2032 (Photo courtesy of 123RF)

Global Fully Automatic Electrolyte Analyzers Market Driven by Surge in Demand for Point-of-Care Testing

Fully automatic electrolyte analyzers can measure the levels of electrolytes in various bodily fluids like blood and plasma. Electrolytes are ions that have an electrical charge and are essential for multiple... Read more
Copyright © 2000-2023 Globetech Media. All rights reserved.